Genfit S.A. GNFT.PA Stock
Genfit S.A. Price Chart
Genfit S.A. GNFT.PA Financial and Trading Overview
| Genfit S.A. stock price | 3.32 EUR |
| Previous Close | 4.2 EUR |
| Open | 4.2 EUR |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 4.13 - 4.2 EUR |
| 52 Week Range | 3.03 - 4.77 EUR |
| Volume | 35.36K EUR |
| Avg. Volume | 97.57K EUR |
| Market Cap | 206.57M EUR |
| Beta (5Y Monthly) | 0.91839 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8 EUR |
GNFT.PA Valuation Measures
| Enterprise Value | 139.47M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.8703833 |
| Price/Book (mrq) | 2.179285 |
| Enterprise Value/Revenue | 5.314 |
| Enterprise Value/EBITDA | -5.388 |
Trading Information
Genfit S.A. Stock Price History
| Beta (5Y Monthly) | 0.91839 |
| 52-Week Change | 34.45% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.77 EUR |
| 52 Week Low | 3.03 EUR |
| 50-Day Moving Average | 3.74 EUR |
| 200-Day Moving Average | 3.83 EUR |
GNFT.PA Share Statistics
| Avg. Volume (3 month) | 97.57K EUR |
| Avg. Daily Volume (10-Days) | 107.97K EUR |
| Shares Outstanding | 49.84M |
| Float | 41.09M |
| Short Ratio | N/A |
| % Held by Insiders | 13.23% |
| % Held by Institutions | 2.73% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -90.37% |
| Operating Margin (ttm) | -105.29% |
| Gross Margin | 100.00% |
| EBITDA Margin | -98.62% |
Management Effectiveness
| Return on Assets (ttm) | -6.94% |
| Return on Equity (ttm) | -22.20% |
Income Statement
| Revenue (ttm) | 26.25M EUR |
| Revenue Per Share (ttm) | 0.53 EUR |
| Quarterly Revenue Growth (yoy) | -82.79% |
| Gross Profit (ttm) | 26.25M EUR |
| EBITDA | -25884000 EUR |
| Net Income Avi to Common (ttm) | -23719000 EUR |
| Diluted EPS (ttm) | -0.48 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 140.55M EUR |
| Total Cash Per Share (mrq) | 2.83 EUR |
| Total Debt (mrq) | 75.28M EUR |
| Total Debt/Equity (mrq) | 79.63 EUR |
| Current Ratio (mrq) | 4.025 |
| Book Value Per Share (mrq) | 1.902 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -72638000 EUR |
| Levered Free Cash Flow (ttm) | -52878376 EUR |
Profile of Genfit S.A.
| Country | France |
| State | N/A |
| City | Loos |
| Address | Parc EurasantE |
| ZIP | 59120 |
| Phone | 33 3 20 16 40 00 |
| Website | https://www.genfit.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 148 |
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Q&A For Genfit S.A. Stock
What is a current GNFT.PA stock price?
Genfit S.A. GNFT.PA stock price today per share is 3.32 EUR.
How to purchase Genfit S.A. stock?
You can buy GNFT.PA shares on the Paris exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genfit S.A.?
The stock symbol or ticker of Genfit S.A. is GNFT.PA.
Which industry does the Genfit S.A. company belong to?
The Genfit S.A. industry is Biotechnology.
How many shares does Genfit S.A. have in circulation?
The max supply of Genfit S.A. shares is 49.86M.
What is Genfit S.A. Price to Earnings Ratio (PE Ratio)?
Genfit S.A. PE Ratio is now.
What was Genfit S.A. earnings per share over the trailing 12 months (TTM)?
Genfit S.A. EPS is -0.58 EUR over the trailing 12 months.
Which sector does the Genfit S.A. company belong to?
The Genfit S.A. sector is Healthcare.
Genfit S.A. GNFT.PA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
| CAC Mid 60 CM100 | 14640.46 EUR 16004 USD |
-0.34
|
— — | — — | — — | — - | — — |
| SBF 120 SBF120 | 6059.85 EUR 6624.23 USD |
-0.18
|
— — | — — | — — | — - | — — |
| CAC Mid & Small MS190 | 14267.59 EUR 15596.4 USD |
-0.38
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}